Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Dalmau, A. Gleichman, Ethan Hughes, J. Rossi, Xiaoyu Peng, Meizan Lai, S. Dessain, M. Rosenfeld, R. Balice-Gordon, D. Lynch (2008)
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodiesThe Lancet Neurology, 7
C. Zarate, Jaskaran Singh, P. Carlson, N. Brutsche, R. Ameli, D. Luckenbaugh, D. Charney, H. Manji (2006)
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.Archives of general psychiatry, 63 8
J. Coyle (2006)
Glutamate and Schizophrenia: Beyond the Dopamine HypothesisCellular and Molecular Neurobiology, 26
Jaime Hallak, J. Maia-de-Oliveira, J. Abrão, P. Evora, A. Zuardi, J. Crippa, P. Belmonte-de-Abreu, G. Baker, S. Dursun (2013)
Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial.JAMA psychiatry, 70 7
G. Tsai, Pao-Yen Lin (2010)
Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.Current pharmaceutical design, 16 5
Craig Karson, W. Griffin, R. Mrak, Mohammed Husain, Ted Dawson, Solomon Snyder, Norman Moore, William Sturner (1996)
Nitric oxide synthase (NOS) in schizophrenia: increases in cerebellar vermis.Molecular and chemical neuropathology, 27 3
A. Pinkham, J. Loughead, K. Ruparel, Wen-Chau Wu, E. Overton, R. Gur, R. Gur (2011)
Resting quantitative cerebral blood flow in schizophrenia measured by pulsed arterial spin labeling perfusion MRIPsychiatry Research: Neuroimaging, 194
K. Do, J. Cabungcal, Anita Frank, P. Steullet, M. Cuénod (2009)
Redox dysregulation, neurodevelopment, and schizophreniaCurrent Opinion in Neurobiology, 19
S. Jaffrey, S. Snyder (1995)
Nitric oxide: a neural messenger.Annual review of cell and developmental biology, 11
Opinion Editorial Nitric Oxide and Symptom Reduction in Schizophrenia Joseph T. Coyle, MD In this issue of the journal, Hallak et al report results from a A remarkable finding was the persistent improvement in placebo-controlled clinical trial showing that infusion of symptoms for 2 weeks after the single dose of nitroprusside. sodium nitroprusside causes a rapid and persistent reduc- The authors rightfully express caution about this finding (the tion of symptoms in patients data were requested by the reviewers) because the blind had with schizophrenia who have been broken before this period of observation and the pa- Related article page 668 been symptomatically stabi- tients had undergone unblinded medication adjustments. lized with antipsychotic medications. The peer reviewers of However, such a persistent effect after a single-dose treat- the manuscript concurred that the study pointed to a poten- ment is not unprecedented. Recent research has demon- tially new avenue for pharmacologic intervention in schizo- strated that a single dose of the NMDA receptor antagonist ket- phrenia, although they recognized that the small number of amine when given to patients with drug-resistant depression patients studied was a serious limitation. It is true that the can produce a rapid improvement in mood
JAMA Psychiatry – American Medical Association
Published: Jul 1, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.